Objective To explore the role of radiotherapy in the treatment of primary central nervous system lymphoma. Methods Clinical data of 60 patients diagnosed with primary central nervous system lymphoma from September 2010 to December 2017 were retrospectively analyzed. Among them, 50 cases were diagnosed by histopathological examination after stereotactic biopsy or tumor resection and 10 patients were diagnosed by gadolinium enhanced magnetic resonance imaging (MRI). Fifty-two patients underwent chemotherapy,and 45 of them received methotrexate-based chemotherapy,25 received rituximab-based regimen. Twenty-seven patients were given with planned whole brain radiotherapy, while 33 patients were not. Salvage radiotherapy was delivered in 9 patients after treatment failure. Results The median follow-up time was 28 months (5-70 months). The median overall survival time and median progression-free survival time of the whole patients was 22 months (5-65 months) and 13 months (5-55 months), respectively. The 4-year overall survival rate and progression-free survival rate were 61% and 33%, respectively. The 4-year overall survival rates between patients with and without planned whole brain radiotherapy were 68% and 54%(P=0.083). The 4-year progression-free survival rates between patients with and without planned whole brain radiotherapy were 47% and 20%(P=0.014),respectively. Patients with and without salvage whole brain radiotherapy had a 4-year overall survival of 49% and 68%,respectively (P=0.398). Among patients who received whole brain radiotherapy,patients with a lower dose of ≤36 Gy had a similar overall survival compared with those with a higher dose of>36 Gy (80% vs. 45%,P=0.136). Conclusions Radiotherapy is part of the comprehensive treatment of primary central nervous system lymphoma. Planned radiotherapy may bring clinical benefits to patients during the comprehensive therapy. However,the irradiation dose to the whole brain should not be too high because of neurotoxicity.
Fan Chengcheng,Ge Hong,Liu Hailong et al. The role of radiotherapy in primary central nervous system lymphoma[J]. Chinese Journal of Radiation Oncology, 2019, 28(8): 593-596.
[1] Low S,Batchelor TT. Primary Central Nervous System Lymphoma[J]. Semin Neurol,2018,38(1):86-94. DOI:10.1055/s-0038-1627470.
[2] Thiel E,Korfel A,Martus P,et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1):a phase 3,randomised,non-inferiority trial[J]. Lancet Oncol,2010,11(11):1036-1047. DOI:10.1016/S1470-2045(10)70229-1.
[3] Cabanillas F. How important is whole brain radiotherapy for treatment of primary CNS lymphoma?[J]. Lancet Oncol,2010,11(11):1011-1012. DOI:10.1016/S1470-2045(10)70234-5.
[4] Omuro A,Taillandier L,Chinot O,et al. Primary CNS lymphoma in patients younger than 60:can whole-brain radiotherapy be deferred?[J]. J Neurooncol,2011,104(1):323-330. DOI:10.1007/s11060-010-0497-x.
[5] Nelson DF,Martz KL,Bonner H,et al. Non-Hodgkin′s lymphoma of the brain:can high dose,large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG):RTOG 8315[J]. Int J Radiat Oncol Biol Phys,1992,23(1):9-17.
[6] DeAngelis LM,Yahalom J,Thaler HT,et al. Combined modality therapy for primary CNS lymphoma[J]. J Clin Oncol,1992,10(4):635-643. DOI:10.1200/JCO.1992.10.4.635.
[7] DeAngelis LM,Seiferheld W,Schold SC,et al. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma:Radiation Therapy Oncology Group Study 93-10[J]. J Clin Oncol,2002,20(24):4643-4648. DOI:10.1200/JCO.2002.11.013.
[8] Gavrilovic IT,Hormigo A,Yahalom J,et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma[J]. J Clin Oncol,2006,24(28):4570-4574. DOI:10.1200/JCO.2006.06.6910.
[9] Poortmans PM,Kluin-Nelemans HC,Haaxma-Reiche H,et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma:European Organization for Research and Treatment of Cancer Lymphoma Group Phase Ⅱ Trial 20962[J]. J Clin Oncol,2003,21(24):4483-4488. DOI:10.1200/JCO.2003.03.108.
[10] Ferreri AJ,Reni M,Foppoli M,et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma:a randomised phase 2 trial[J]. Lancet,2009,374(9700):1512-1520. DOI:10.1016/S0140-6736(09)61416-1.
[11] Kim BH,Kim IH,Park SH,et al. Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma[J]. Cancer Res Treat,2014,46(3):261-269. DOI:10.4143/crt.2014.46.3.261.
[12] Ferreri AJ,Verona C,Politi LS,et al. Consolidation radiotherapy in primary central nervous system lymphomas:impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy[J]. Int J Radiat Oncol Biol Phys,2011,80(1):169-175. DOI:10.1016/j.ijrobp.2010.01.066.
[13] Shah GD,Yahalom J,Correa DD,et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma[J]. J Clin Oncol,2007,25(30):4730-4735. DOI:10.1200/JCO.2007.12.5062.
[14] Morris PG,Correa DD,Yahalom J,et al. Rituximab,methotrexate,procarbazine,and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma:final results and long-term outcome[J]. J Clin Oncol,2013,31(31):3971-3979. DOI:10.1200/JCO.2013.50.4910.
[15] Nguyen PL,Chakravarti A,Finkelstein DM,et al. Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma[J]. J Clin Oncol,2005,23(7):1507-1513. DOI:10.1200/JCO.2005.01.161.
[16] Hottinger AF,DeAngelis LM,Yahalom J,et al. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma[J]. Neurology,2007,69(11):1178-1182. DOI:10.1212/01.wnl.0000276986.19602.c1.
2019, Vol. 28 
